{"entity":{"id":"ar-v7-splice-variant","kind":"biomarker","name":"AR-V7 splice variant","aka":["AR-V7","AR-V7 positive","androgen receptor splice variant 7","AR-V7 CTC","nuclear AR-V7"],"tldr":"AR-V7 is a shortened androgen receptor that lacks the part hormone drugs bind, so it stays active without testosterone. Found in circulating tumour cells, it predicts poor response to abiraterone and enzalutamide, but no label uses it yet.","summary":"The AR-V7 transcript skips the ligand-binding domain and is detected by RT-PCR of circulating tumour cell RNA or by nuclear AR-V7 protein immunofluorescence in CTCs (the Oncotype DX AR-V7 Nucleus Detect assay, a laboratory-developed test). The prospective PROPHECY trial (NCT02269982) showed that AR-V7-positive men had shorter progression-free and overall survival on abiraterone or enzalutamide, while taxane response was preserved. No regulator has put AR-V7 in a label and no companion diagnostic exists; it is a guideline-discussed, not guideline-mandated, test.","asOf":"2026-09-23","links":[{"label":"PROPHECY (NCT02269982)","url":"https://clinicaltrials.gov/study/NCT02269982"}],"tags":["biomarker","prostate","no-approval"],"related":["psma-pet-expression"],"cancers":["prostate-mcrpc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","enzalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":["ar-v7"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"androgen-receptor","measurement":"sequencing-variant","scoringRule":{"text":"Detection of the AR-V7 transcript in circulating tumour cell RNA by RT-PCR, or nuclear-localised AR-V7 protein in circulating tumour cells by immunofluorescence; no label defines a threshold.","quote":"AR-V7 splice variant","source":"https://clinicaltrials.gov/study/NCT02269982","sourceLabel":"PROPHECY trial (NCT02269982): prospective validation of AR-V7 in metastatic castration-resistant prostate cancer"},"thresholds":[],"definedBy":{"label":"PROPHECY: AR-V7 in circulating tumour cells predicting resistance to abiraterone and enzalutamide (ClinicalTrials.gov NCT02269982)","url":"https://clinicaltrials.gov/study/NCT02269982"},"tests":[],"assays":[],"companionDiagnostics":[],"forPatient":"An AR-V7-positive result suggests that abiraterone and enzalutamide are less likely to work and that chemotherapy or a radioligand may be a better next step, but no approval depends on it and it is not routinely offered outside specialist centres. A negative result does not guarantee response."},"route":"/biomarkers/ar-v7-splice-variant/","neighbours":{"biomarker":[{"id":"psma-pet-expression","kind":"biomarker","name":"PSMA expression by PET (PSMA-positive)","route":"/biomarkers/psma-pet-expression/"}],"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"}],"term":[{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}]}}